Moderna (MRNA) Stock Jumps After Hantavirus Outbreak Sparks Biotech Rally

TLDR

• Moderna stock rose over 8% in premarket trading Monday after a U.S. national tested positive for the Andes hantavirus strain
• Moderna confirmed it is conducting “early-stage and ongoing” preclinical research on hantavirus in collaboration with USAMRIID
• Inovio jumped 13%, Novavax rose 3%, and Emergent Biosolutions gained 4% in early trading
• WHO has assessed the public health risk as low — eight cases reported, three deaths, five confirmed as hantavirus
• Evercore ISI analysts said they see “no meaningful revenue opportunity” for Moderna from the outbreak

The rally in Moderna stock has more to do with investor sentiment than science right now.

Moderna (MRNA) jumped 8.5% to around $58.99 in Monday premarket trading, continuing a run that started Friday when the stock climbed 12%. From its 52-week closing low of $22.26 in November 2025, the stock has now risen roughly 161%.

Moderna, Inc., MRNA

The catalyst: a U.S. national on board the MV Hondius cruise ship tested positive for the Andes strain of hantavirus, a rare rodent-borne respiratory virus that is the only hantavirus strain capable of human-to-human transmission.

The Department of Health and Human Services confirmed that all 17 American citizens from the ship are being repatriated to the U.S. Two passengers are traveling in biocontainment units on the repatriation flight — one tested mildly positive, another is showing mild symptoms.

That’s enough for markets to run with it — at least for now.

Analysts Push Back on the Rally

The broader biotech space moved too. Inovio Pharmaceuticals (INO) jumped 13% in early trading. Novavax (NVAX) gained around 3%, and Emergent Biosolutions (EBS) was up roughly 4%.

The WHO flagged the outbreak on May 2 after passengers on the Dutch-flagged expedition ship contracted the virus while sailing the Atlantic. WHO Director General Tedros Adhanom Ghebreyesus confirmed eight cases total — five confirmed as hantavirus — and three deaths. The WHO assessed the public health risk as low.

What We Know About the Outbreak

The MV Hondius has since docked in Tenerife in Spain’s Canary Islands. Passengers and crew have disembarked under strict health protocols, with coordinated testing, isolation, and repatriation efforts underway across multiple countries.

Health authorities have been consistent: human-to-human transmission of the Andes strain is rare, and the risk of a wider outbreak remains low.

Moderna is now on track for its highest close since October 2024 if premarket gains hold into the session.

The post Moderna (MRNA) Stock Jumps After Hantavirus Outbreak Sparks Biotech Rally appeared first on CoinCentral.